Last update April 15, 2024

Nicardipine Hydrochloride


Safe substance and/or breastfeeding is the best option.

It is a dihydropyridine-type calcium channel blocker with actions similar to those of nifedipine. It is used in the treatment of hypertension, angina pectoris, postoperative hypertension, and severe preeclampsia. Oral administration three times a day or intravenous infusion.

Its excretion into breast milk is almost null (undetectable in 82% of cases) or in clinically non-significant amount. (Matsumura 2014, Bartels 2007, Jarreau 2000), possibly due to its high percentage of plasmatic protein binding and very wide volume of distribution.

Several medical societies and expert authors consider the use of this medication possible during breastfeeding. (Hale, LactMed, Briggs 2015, Schaefer 2015, Serrano 2015)


  • Nifedipine (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Nicardipine Hydrochloride in other languages or writings:


Nicardipine Hydrochloride belongs to these groups or families:


Main tradenames from several countries containing Nicardipine Hydrochloride in its composition:


Variable Value Unit
Oral Bioavail. 35 %
Molecular weight 480 daltons
Protein Binding 99 %
VD 2 - 8 l/Kg
pKa 16.97 -
Tmax 0.5 - 2 hours
8.6 hours
M/P ratio 0.06 - 0.3 -
Theoretical Dose 0.0008 - 0.003 mg/Kg/d
Relative Dose 0.08 - 0.18 %
Ped.Relat.Dose 0.1 - 0.4 %


  1. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: 2006 - Consulted on April 16, 2024 Full text (link to original source)
  2. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on April 10, 2024 Full text (link to original source)
  3. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  4. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  5. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, Third Edition. 2015
  6. Matsumura H, Takagi K, Seki H, Ono Y, Ichinose S, Masuko H, Fukatsu M, Miyashita A, Mera A. Placental transfer of intravenous nicardipine and disposition into breast milk during the control of hypertension in women with pre-eclampsia. Hypertens Pregnancy. 2014 Abstract
  7. Bartels PA, Hanff LM, Mathot RA, Steegers EA, Vulto AG, Visser W. Nicardipine in pre-eclamptic patients: placental transfer and disposition in breast milk. BJOG. 2007 Abstract Full text (link to original source) Full text (in our servers)
  8. Jarreau P, Beller CL, Guillonneau M, Jacqz-Aigrain E. Excretion of nicardipine in human milk. Paediatr Perinat Drug Ther. 2000;4(1):28-30.

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM